Besremi for ET – pro
BESREMi (ropeginterferon alfa-2b-njft) is an interferon indicated for treating adults with polycythemia vera (PV). It is nto indicated for Essential Thrombocythemia. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology now include Besremi (ropeginterferon alfa-2b-njft) as a Category 1 preferred treatment option for certain high-risk patients with essential thrombocythemia (ET) who have not responded adequately to existing therapies or whose response has diminished over time.
Masarova L, Gill H, Zhang L, et al. Phase 3 study comparing ropeginterferon alfa-2b with anagrelide as second-line treatment for essential thrombocythemia: SURPASS-ET trial. Presented at: 2025 SOHO Annual Meeting; September 3-6, 2025; Houston, TX. Abstract MPN-524.
Okikiolu J, Woodley C, Cadman-Davies L, O’Sullivan J, Radia D, Garcia NC, Harrington P, Kordasti S, Asirvatham S, Sriskandarajah P, Saunders J, Saha C, Sanchez I, deLavallade H, McLornan DP, Harrison CN. Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys). Leuk Res Rep. 2022 Dec 16;19:100360. doi: 10.1016/j.lrr.2022.100360. PMID: 36590864; PMCID: PMC9801096.
NCCN Myeloproliferative 2026